Answers are grounded in this paper and cite their sources.
Pancreatic ductal adenocarcinoma (PDAC) develops in a nutrient-poor microenvironment and progresses from pancreatic intraepithelial neoplasia (PanIN) to invasive carcinoma. Serine metabolism supports tumor growth in many cancers, spurring the development of inhibitors of phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in serine biosynthesis. However, the limited clinical success of PHGDH inhibitors highlights the need to better understand the stage-specific role of de novo serine synthesis during PDAC progression. Here, we showed that PHGDH increases progressively from PanIN to invasive PDAC in human and mouse tissues. In genetically engineered mouse models with inducible PHGDH knockdown, PHGDH loss delayed PDAC development. Acute treatment with the PHGDH inhibitor BI-9593 suppressed de novo serine synthesis, induced cell death, and drove tumor regression. Unexpectedly, PHGDH-deficient tumors did not become more dependent on exogenous serine, and dietary serine/glycine manipulation did not affect tumor development. Instead, stable isotope tracing and metabolomic profiling showed that PHGDH loss reduced ASCT2 expression and impaired glutamine uptake and utilization, creating a metabolic liability that rendered PHGDH-deficient tumors selectively sensitive to the glutamine antagonist DRP-104. Together, these findings reveal a therapeutic vulnerability to combined metabolic targeting in PDAC.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: